Investor Relations

Company Profile

ResApp Health Limited (ASX:RAP) is developing healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease on smartphones without the need for additional hardware. ResApp’s core technology uses sound to diagnose respiratory diseases including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease and asthma.


Level 12, 100 Creek St
Brisbane, QLD 4000

Registered Office

Level 24, 44 St Georges Tce
Perth, WA 6000

Board of Directors

Dr Roger Aston – Non-Executive Chairman
Dr Tony Keating – Chief Executive Officer and Managing Director
Nathan Buzza – Non-Executive Director
Chris Ntoumenopoulos – Non-Executive Director


Australian Securities Exchange
ASX code: RAP

Share price

Please refer to the ASX website for current share price and history.

Share Registry

Link Market Services Limited
Level 12 QV1 Building
250 St Georges Terrace
Perth WA 6000

Investor Relations Contact

Brian Leedman
VP, Corporate Affairs
+61 412 281 780

ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 12, 100 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000

+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations


Terms of Use
Privacy Policy

ResAppDx-US is pending review of a request for De Novo classification and is not available for sale in the United States.

© 2019 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries.